Lymphoma — Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT
Citation(s)
Safety Trial of Natural Killer (NK) Cell Donor Lymphocyte Infusions (DLI) From 3-5/6 Human Leukocyte Antigen (HLA) Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation (ASCT)